Senologie - Zeitschrift für Mammadiagnostik und -therapie 2025; 22(02): e16
DOI: 10.1055/s-0045-1807665
Abstracts

Chemotherapy-induced nausea and vomiting (CINV) in adjuvant chemotherapy with FEC followed by Docetaxel versus anthracycline free regimen with Docetaxel/ Cyclophosphamide in early breast cancer patients – A detailed examination of various endpoints and their trajectories over time<

Authors

  • M Hörner

    1   University Hospital Erlangen, Department of Obstetrics and Gynaecology, Erlangen, Deutschland
  • P Ziegler

    1   University Hospital Erlangen, Department of Obstetrics and Gynaecology, Erlangen, Deutschland
  • S Brucker

    2   University of Tuebingen, Department of Obstetrics and Gynecology, Tuebingen, Deutschland
  • L Häberle

    1   University Hospital Erlangen, Department of Obstetrics and Gynaecology, Erlangen, Deutschland
  • G Heinrich

    3   Klinikum Offenbach, Schwerpunktpraxis der Gynäkologie und Onkologie Fürstenwalde, Fürstenwalde, Deutschland
  • U Köhler

    4   Klinikum St. Georg, Klinik für Gynäkologie und Geburtshilfe, Leipzig, Deutschland
  • E Leinert

    5   University of Ulm, Department of Obstetrics and Gynaecology, Ulm, Deutschland
  • K Pfister

    5   University of Ulm, Department of Obstetrics and Gynaecology, Ulm, Deutschland
  • H Schäffler

    5   University of Ulm, Department of Obstetrics and Gynaecology, Ulm, Deutschland
  • K Veselinovic

    5   University of Ulm, Department of Obstetrics and Gynaecology, Ulm, Deutschland
  • M W Beckmann

    1   University Hospital Erlangen, Department of Obstetrics and Gynaecology, Erlangen, Deutschland
  • P A Fasching

    1   University Hospital Erlangen, Department of Obstetrics and Gynaecology, Erlangen, Deutschland
  • W Janni

    5   University of Ulm, Department of Obstetrics and Gynaecology, Ulm, Deutschland
  • B Rack

    5   University of Ulm, Department of Obstetrics and Gynaecology, Ulm, Deutschland
  • S Heublein

    5   University of Ulm, Department of Obstetrics and Gynaecology, Ulm, Deutschland
 
 

    Background: Patients included in the SUCCESS C trial with HER2neg early breast cancer received either 3 cycles of FEC, followed by 3 cycles of docetaxel or 6 cycles of docetaxel, cyclophosphamide (DC) adjuvant chemotherapy. This analysis focuses on CINV-rates evaluating if different endpoints differed between the two regimens and how they developed over the course of cycles.

    Materials and Methods: Of the 3463 patients included in the SUCCESS C trial 1508 patients were accessible for this analysis with complete cycle documentation. CINV was evaluated using a tailored questionnaire on an hourly basis for the first 5 days after receiving chemotherapy. Endpoints were no control (NC), complete response (CR, no vomiting, retching, rescue medication), complete control (CC, CR+no significant nausea) and total control (TC, CR+no nausea).

    Results: 767 and 741 patients received FEC and DC, respectively, and were both examined for cycles 1 to 3 for better comparability. For patients receiving FEC TC increased from 20% (c1) to 27.6% (c3), while no control decreased from 43.8% (c1) to 37.9%. For patients receiving DC TC increased from 39.1% (c1) to 49.7% (c3), while no control decreased from 27% (c1) to 24%. In both groups, an intensive crossover between the endpoints took place.

    Conclusion: This is one of the largest prospective studies on CINV, with high temporal resolution and detailed data on different endpoints. Improvement of CINV-control is shown in both groups in the first 3 cycles, possibly due to suboptimal antiemetic prophylaxis recommendations.


    Interessenskonflikt

    Ich erkläre als korrespondierende/r AutorIn, dass meine Ko-AutorenInnen mir mitgeteilt haben, dass sie während der letzten 3 Jahre keine wirtschaftlichen oder persönlichen Verbindungen im oben genannten Sinne hatten. Auch ich selbst hatte keine derartigen Verbindungen in den letzten 3 Jahren.

    Publication History

    Article published online:
    04 June 2025

    © 2025. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany